Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Labcorp (NYSE: LH) has launched a new sponsored testing program for advanced non-small cell lung cancer (NSCLC) patients, enhancing access to precision medicine. This initiative aims to aid informed treatment decisions by utilizing Labcorp’s OmniSeq INSIGHT test, which provides comprehensive genomic and immune profiling. Sponsored by Eli Lilly, the program seeks to identify actionable biomarkers, potentially improving patient outcomes and expanding eligibility for clinical trials. Labcorp's commitment to precision medicine is highlighted through this collaboration, furthering advancements in cancer care.
Labcorp (NYSE: LH) has launched a new test measuring LAG-3 expression in melanoma patients, which could enhance treatment options. This assay, developed for clinical trials, provides critical data for evaluating new cancer therapies, particularly those targeting LAG-3. Labcorp aims to improve patient care by offering diagnostic solutions that guide clinical decisions. With skin cancer being the most common cancer in the U.S., this advancement represents a significant step in combating melanoma. The assay's clinical application could lead to improved patient outcomes.
Labcorp (NYSE: LH) has received Emergency Use Authorization (EUA) from the FDA for a new at-home collection kit that tests for COVID-19, influenza A/B, and RSV. This combined kit offers reliable PCR testing from the comfort of home, aimed at individuals aged 2 and older. Tests can be ordered through Labcorp OnDemand without a prescription and may incur no upfront cost for those with insurance. Labcorp has conducted over 74 million COVID-19 tests and continues to innovate in response to respiratory virus prevalence.
Labcorp (NYSE: LH), a global life sciences leader, will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on May 24 at 2:45 p.m. ET. A live webcast will be available on the Labcorp Investor Relations website. With over 75,000 employees and a revenue of $16 billion in 2021, Labcorp provides critical diagnostic and drug development insights worldwide.
Labcorp has launched an at-home Diabetes Risk Test Kit through Labcorp OnDemand, offering a convenient way for individuals to assess their diabetes risk. The test utilizes a new blood collection device, Weavr Velvet, which has received approval for HbA1c testing from New York State. This easy-to-use kit allows consumers to collect a small blood sample at home, with results showing over 97% accuracy compared to traditional blood draws. This initiative aims to empower more Americans to understand and manage their health regarding diabetes.
Labcorp (NYSE: LH) has finalized a transaction to acquire assets from AtlantiCare's clinical outreach business, enhancing their collaboration to serve patients in Southern New Jersey. This move expands Labcorp's diagnostic capabilities and patient access through various service centers, including Labcorp at Walgreens. The partnership aims to improve health services and patient care, especially post-pandemic. Labcorp reported a revenue of $16 billion in FY2021, reinforcing its position in the healthcare market.
Labcorp (NYSE: LH) will hold its Annual Meeting of Shareholders on May 11 at 9:00 a.m. ET, which will be webcast live via the Labcorp Investor Relations website. An archived replay of the meeting will be available for one year. Labcorp is a global leader in life sciences, offering vital information to assist healthcare professionals and researchers in making informed decisions. The company reported $16 billion in revenue for 2021 and operates in over 100 countries with a workforce exceeding 75,000 employees.
Labcorp (NYSE: LH) reported Q1 revenue of $3.9 billion, a 6.3% decline from $4.16 billion last year, with diluted EPS of $5.23, down from $7.82. Adjusted EPS also decreased to $6.11 from $8.79. The company announced a quarterly dividend of $0.72 per share and updated its full-year guidance for adjusted EPS to $18.25-$21.00. The decline in revenue was driven by a 9.8% reduction in COVID-19 testing. Despite these challenges, Labcorp is focusing on organic growth, highlighted by the launch of the Labcorp OnDemand platform and new strategic health collaborations.
Labcorp has announced a collaboration with Getlabs, launching Getlabs for Labcorp, an innovative at-home phlebotomy service. This service allows consumers to schedule blood draws or specimen collections at their convenience, now available in over 50 U.S. markets. The initiative aims to enhance accessibility to diagnostic testing, particularly for those with mobility challenges or busy schedules. Getlabs charges a convenience fee starting at $25, and together, they offer more than 5,000 diagnostic tests, improving health care access amid ongoing challenges.
Labcorp (NYSE: LH) announces a strategic collaboration with Xcell Biosciences, Inc. to enhance the development of cell and gene therapies (CGTs). This partnership aims to improve the safety and efficacy of CGTs and will involve projects utilizing Xcellbio’s AVATAR incubator system. The collaboration aligns with Labcorp’s commitment to advancing CGT capabilities and supporting pharmaceutical companies in accelerating therapeutic development. Labcorp, with over 20 years of experience, has been instrumental in supporting the development of FDA-approved CAR-T cell and gene therapies.